Steel Partners makes unsolicited bid for InMode
Steel Partners launched an unsolicited bid to acquire InMode, a medical aesthetics and wellness technology company, on July 9. InMode formed a special committee to review the bid’s fairness and protec
Steel Partners Holdings L.P. has launched an unsolicited acquisition bid for InMode Ltd., the leading medical aesthetics and wellness technology compa
Read Full Story at Nasdaq News →Why This Matters
The unsolicited bid from Steel Partners underscores the accelerating consolidation in the medical aesthetics sector, where high-margin, innovative technologies are increasingly drawing interest from private equity and strategic acquirers. For InMode, a leader in non-invasive body contouring and skin rejuvenation solutions, this bid highlights the company's strategic value as a potential acquisition target amid a competitive market for aesthetic technology assets.
Background Context
InMode has established itself as a dominant player in the medical aesthetics space, with a portfolio spanning laser-based treatments, radiofrequency devices, and aesthetic surgery tools. The company's growth has been fueled by rising consumer demand for non-surgical cosmetic procedures, particularly in post-pandemic markets where wellness and self-improvement have gained cultural prominence. Steel Partners, known for its activist investing and opportunistic acquisitions, has not previously targeted medical technology firms, making this bid a notable departure from its typical strategy.
What Happens Next
The formation of a special committee suggests InMode will scrutinize the bid's valuation and strategic alternatives, which could lead to a counteroffer, negotiation, or rejection. Steel Partners' unsolicited approach may pressure InMode's board to explore a sale, especially if shareholders push for liquidity in a market where premiums for high-growth medtech firms remain elevated. Observers will watch whether InMode pursues organic growth strategies or seeks alternative partnerships to bolster its independence.
Bigger Picture
This deal reflects broader consolidation trends in healthcare technology, where private equity firms are increasingly targeting niche medical device companies with scalable, recurring-revenue models. The medical aesthetics sector, in particular, has seen a surge in M&A activity driven by demographic shifts, regulatory tailwinds, and the rise of "preventive wellness" as a mainstream consumer priority. If successful, this bid could set a precedent for further private equity interest in adjacent medtech segments.
